DE69926632D1 - Tetrahydrochinolinderivate als glycin antagonisten - Google Patents

Tetrahydrochinolinderivate als glycin antagonisten

Info

Publication number
DE69926632D1
DE69926632D1 DE69926632T DE69926632T DE69926632D1 DE 69926632 D1 DE69926632 D1 DE 69926632D1 DE 69926632 T DE69926632 T DE 69926632T DE 69926632 T DE69926632 T DE 69926632T DE 69926632 D1 DE69926632 D1 DE 69926632D1
Authority
DE
Germany
Prior art keywords
glycine antagonists
tetrahydrochinoline
derivatives
tetrahydrochinoline derivatives
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69926632T
Other languages
English (en)
Other versions
DE69926632T2 (de
Inventor
Fabio Romano Di
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
GlaxoSmithKline SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9812410.0A external-priority patent/GB9812410D0/en
Priority claimed from GBGB9812408.4A external-priority patent/GB9812408D0/en
Application filed by GlaxoSmithKline SpA filed Critical GlaxoSmithKline SpA
Application granted granted Critical
Publication of DE69926632D1 publication Critical patent/DE69926632D1/de
Publication of DE69926632T2 publication Critical patent/DE69926632T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
DE69926632T 1998-06-10 1999-06-08 Tetrahydrochinolinderivate als glycinantagonisten Expired - Lifetime DE69926632T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9812408 1998-06-10
GB9812410 1998-06-10
GBGB9812410.0A GB9812410D0 (en) 1998-06-10 1998-06-10 Heterocyclic derivatives
GBGB9812408.4A GB9812408D0 (en) 1998-06-10 1998-06-10 Heterocyclic compounds
PCT/EP1999/003936 WO1999064411A1 (en) 1998-06-10 1999-06-08 Tetrahydroquinoline derivatives as glycine antagonists

Publications (2)

Publication Number Publication Date
DE69926632D1 true DE69926632D1 (de) 2005-09-15
DE69926632T2 DE69926632T2 (de) 2006-01-19

Family

ID=26313826

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69926632T Expired - Lifetime DE69926632T2 (de) 1998-06-10 1999-06-08 Tetrahydrochinolinderivate als glycinantagonisten

Country Status (34)

Country Link
US (3) US6362199B1 (de)
EP (1) EP1086093B1 (de)
JP (1) JP2002517492A (de)
KR (1) KR100586762B1 (de)
CN (1) CN1173970C (de)
AP (1) AP2000002008A0 (de)
AR (1) AR018632A1 (de)
AT (1) ATE301650T1 (de)
AU (1) AU753867B2 (de)
BG (1) BG105123A (de)
BR (1) BR9911145A (de)
CA (1) CA2334727C (de)
CO (1) CO5080785A1 (de)
CZ (1) CZ293605B6 (de)
DE (1) DE69926632T2 (de)
DK (1) DK1086093T3 (de)
EA (1) EA003276B1 (de)
EE (1) EE200000733A (de)
ES (1) ES2249010T3 (de)
HK (1) HK1034079A1 (de)
HR (1) HRP20000845A2 (de)
HU (1) HUP0102767A3 (de)
ID (1) ID27845A (de)
IL (2) IL140062A0 (de)
IS (1) IS5746A (de)
MY (1) MY125037A (de)
NO (1) NO321904B1 (de)
NZ (1) NZ508638A (de)
OA (1) OA11564A (de)
PE (1) PE20000724A1 (de)
PL (1) PL197160B1 (de)
TR (1) TR200003652T2 (de)
TW (1) TWI229079B (de)
WO (1) WO1999064411A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10000311A1 (de) 2000-01-05 2001-07-12 Gruenenthal Gmbh Aminomethyl-Phonyl-Cyclohexanonderivate
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
DE10137488A1 (de) * 2001-08-03 2003-02-20 Gruenenthal Gmbh Salze substituierter 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
DE10137487A1 (de) * 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
PL376156A1 (en) * 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
GB0327912D0 (en) * 2003-12-02 2004-01-07 Glaxo Group Ltd Medicament
UA90706C2 (ru) * 2005-02-24 2010-05-25 Милленниум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2024516C1 (ru) * 1989-02-02 1994-12-15 Яманути Фармасьютикал Ко., Лтд. Способ получения производного тетрагидробензимидазола или его фармацевтически приемлемой соли
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
EP0386839B1 (de) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5529999A (en) 1994-03-04 1996-06-25 Eli Lilly And Company Antitumor compositions and methods of treatment
BR9610733A (pt) 1995-09-29 1999-07-13 Glaxo Wellcome Spa Composto processos para a preparação do mesmo e para o tratamento de um mamífero composição farmacêutica e utilização de um composto
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
US6413985B1 (en) 2002-07-02
TWI229079B (en) 2005-03-11
EE200000733A (et) 2002-06-17
MY125037A (en) 2006-07-31
AR018632A1 (es) 2001-11-28
PL197160B1 (pl) 2008-03-31
HUP0102767A3 (en) 2003-01-28
CZ293605B6 (cs) 2004-06-16
OA11564A (en) 2004-05-24
NO20006227L (no) 2001-02-08
BR9911145A (pt) 2001-03-06
ATE301650T1 (de) 2005-08-15
AU4509299A (en) 1999-12-30
DK1086093T3 (da) 2005-11-28
US20020169186A1 (en) 2002-11-14
CN1311785A (zh) 2001-09-05
PE20000724A1 (es) 2000-08-17
EP1086093A1 (de) 2001-03-28
IL140062A (en) 2007-05-15
ES2249010T3 (es) 2006-03-16
AU753867B2 (en) 2002-10-31
CA2334727A1 (en) 1999-12-16
JP2002517492A (ja) 2002-06-18
DE69926632T2 (de) 2006-01-19
NZ508638A (en) 2003-08-29
WO1999064411A1 (en) 1999-12-16
HRP20000845A2 (en) 2001-10-31
CA2334727C (en) 2009-08-04
US6362199B1 (en) 2002-03-26
TR200003652T2 (tr) 2001-04-20
HUP0102767A2 (hu) 2001-12-28
CZ20004587A3 (en) 2001-05-16
AP2000002008A0 (en) 2000-12-31
EA003276B1 (ru) 2003-04-24
HK1034079A1 (en) 2001-10-12
EP1086093B1 (de) 2005-08-10
IL140062A0 (en) 2002-02-10
CN1173970C (zh) 2004-11-03
IS5746A (is) 2000-11-30
NO20006227D0 (no) 2000-12-07
US20020052391A1 (en) 2002-05-02
KR100586762B1 (ko) 2006-06-08
CO5080785A1 (es) 2001-09-25
NO321904B1 (no) 2006-07-17
KR20010052722A (ko) 2001-06-25
BG105123A (en) 2001-11-30
US6495566B2 (en) 2002-12-17
ID27845A (id) 2001-04-26
EA200001165A1 (ru) 2001-06-25
PL344694A1 (en) 2001-11-19

Similar Documents

Publication Publication Date Title
DE69930518D1 (de) Als antikrebsmittel verwendbare alkinyl-substituierte chinolin-2-on-derivate
PT996622E (pt) Novos compostos heterociclicos espiroazabiciclicos
DK0915088T3 (da) D-prolinderivater
ID22850A (id) Senyawa-senyawa pirazina
DE69829192D1 (de) Neue substituierte imidazolverbindungen
ATE261429T1 (de) Neue 3-aryl-2-hydroxypropionsäure-derivate iii
ID23168A (id) Reseptor anatagonis vitronektin
ID20323A (id) Senyawa-senyawa triazinilaminostilbena
ATE221052T1 (de) Tetrahydrochinolinderivate als eaa antagonisten
ATE255098T1 (de) Substituierte chromanderivate
DE59813430D1 (de) Perylenhydrazidimide als Carbonylderivatisierungsreagenzien
EE9900448A (et) Ühendid
ATE255099T1 (de) Substituierte chromanderivate
ATE301650T1 (de) Tetrahydrochinolinderivate als glycin antagonisten
EE200000428A (et) VLA-4 antagonistid
DE69735811D1 (de) Piperazinoderivate als neurokinin-antagonisten
EE9900475A (et) Ühendid
DE69829567D1 (de) Angiotensinderivate
DE60012953D1 (de) 3-amino-2-phenylpiperidinderivate als substanz p antagonisten
EE9900602A (et) Ühendid
EE9900466A (et) Ühendid
NO20012283D0 (no) Koblede peptider
DE69737634D1 (de) Insektizide oxadiazinverbindungen
NO20013095L (no) Arrangement for sömforberedelse
FIU980382U0 (fi) Sovitelma kaidejärjestelyksi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition